iiinova — where your digital self keeps evolving

Mark Geyer, M.D. @markgeyermd.bsky.social · 19/07/2026

Congratulations to the Three Lions on their fantastic run and bronze medal finish! Well done lads. #England

Mark Geyer, M.D. @markgeyermd.bsky.social · 08/12/2025

Nosha Farhadfar updates us on ongoing Ph1 multicenter study of SENTI-202, a first-in-class, CD33 and/or FLT3 & not endomucin, selective off-the-shelf logic gated CAR NK cell therapy in 20 adults w/ R/R AML/MDS w/ FLT3 and/or CD33, max 3 prior tx (max 2 for MDS IB). No DLTs seen. (1/2) #ASH25.

140

Mark Geyer, M.D. @markgeyermd.bsky.social · 08/12/2025

Peihua Lu back to the podium to discuss CTD402 (being developed in US by Imviva), a CD7-targeted CAR T-cell product for R/R T-ALL in pediatric/adult pts. Focused on 41 pts in RP2D cohort (400 million cells). 9/41 w/ ETP-ALL, 10/41 w/ prior HCT. 5 pts w/ G3+ CRS; 0 (!) w/ ICANS or HLH. #ASH25 (1/2)

120

Mark Geyer, M.D. @markgeyermd.bsky.social · 08/12/2025

Robert Chiesa of Great Ormond Street presents on allogeneic CD7-targeted "base edited" CAR T-cells for R/R T-ALL (gene editing to disrupt TCRab/CD52/CD7). 11 children enrolled (9 treated) +2 adults; one infusion of CD7 CAR T-cells. 3 w/prior HCT. All w/active BM dz at lymphodepletion. (1/2) #ASh25

110

Mark Geyer, M.D. @markgeyermd.bsky.social · 08/12/2025

Dr. Tingting Yang presents on sequential CD7-targeted CAR T-cell therapy followed by HCT without conditioning and GvHD ppx for 19 pts w/ R/R AML or T-ALL/LBL. aGVHD in 59% as below; 17/19 full donor chimerism at 1 month; 11/19 remain alive (10 in CR). Median PFS/OS 12.3/14.6 months. (1/2) #ASH25

100

Mark Geyer, M.D. @markgeyermd.bsky.social · 08/12/2025

Dr. Peihua Lu presents on CD7 CAR T-cell therapy in 30 pediatric and adult pts w/ R/R T-ALL using NS7CAR (natural selected CD7 CAR product w/o gene editing), all with CNS-2/3 involvement. All received bridging. No manufacturing failure. Vein to vein time 2 weeks. (1/2) median#ASH25

110

Mark Geyer, M.D. @markgeyermd.bsky.social · 08/12/2025

Dr. Quynh Long Khuong from UPenn presents on possible use of BB/ACEi to reduce cardiotoxicity in pediatric pts w/ AML receiving anthracycline-based induction using multicenter cohort. 908 pts studied; modest but significant reduction in LVEF reduction and mortality w/ BB. (1/2) #ASH25

142

Mark Geyer, M.D. @markgeyermd.bsky.social · 08/12/2025

Zachary Graff of @medicalcollegeofwi.bsky.social presents on CNS disease status in pediatric pts w/ AML treated on AAML1831. CNS-1/2/3 (using ALL definition) status predicted EFS when retrospectively applied to prior COG studies. AAML1831 delayed LP to d8 and used more triple IT tx. (1/2) #ASH25

100

Mark Geyer, M.D. @markgeyermd.bsky.social · 08/12/2025

Dr. Talha Badar from @mayocliniccancer.bsky.social presents on selection of HMA for new-dx TP53m AML. 321 pts (138 aza/183 dec), median age 71, no sig diff in genetic profile. Slightly higher CR/CRi (54 vs 39% w/ dec vs aza). EFS/OS similarly poor. Complex CG assoc w/ worse EFS/OS. (1/2) #ASH25

100

Mark Geyer, M.D. @markgeyermd.bsky.social · 08/12/2025

Dr. Quan Do of VCU Healt Systems presents on risk of heart failure (HF) post-idarubicin vs daunorubicin; structurally, ida expected to be less cardiotoxic, though clinical trials haven't suggested the same. TriNetX database used to assess HF rate w/in 10y of AML tx w/ dauno/ida in 7+3. (1/2) #ASH25

100

Mark Geyer, M.D. @markgeyermd.bsky.social · 08/12/2025

Dr. Montesinos presents on "indolent" AML based on PETHEMA registry data. A subset of pts age ≥60y have longer-term survival (≥9 mon) w/ best supportive care (BSC) alone (192/2506). ↓ WBC/PB+BM blasts/LDH, ↑albumin in indolent AML; PLTs/albumin/BM blasts remained sig in multivar analysis. #ASH25

000

Mark Geyer, M.D. @markgeyermd.bsky.social · 08/12/2025

Dr. Douglas Tremblay from Mount Sinai presents on association of nadir bone marrow aspirate (BMA) characteristics w/ reinduction outcomes based on 233 pts from ECOG-ACRIN AML studies (E1900, E2906). Mostly intermediate/adverse risk. Median 15% reduction w/ reinduction, 52% CR w/ reind. (1/2) #ASH25

100

Mark Geyer, M.D. @markgeyermd.bsky.social · 08/12/2025

Aman Wadhwa presents on risk factors for CNS relapse in 21,830 pts w/ de novo B-ALL across COG studies 2004-2019. Certain risk factors for BM relapse (age, female sex) did NOT predict CNS relapse. Cumulative incidence of CNS relapse 2.2%, median time 24.6 months. (1/2) #ASH25

112

Mark Geyer, M.D. @markgeyermd.bsky.social · 08/12/2025

Thai Hoa Tran from CHU Sainte-Justine in Montreal reports on 196 pediatric/AYA pts (age <25y) w/ T-ALL harboring ABL-class fusions (~5% of T-ALL) from multinational retrospective study within Pointe di Legno consortium. 69% w/ NUP214::ABL1, 8% BCR::ABL1. 72% male. Median dx WBC 83. (1/2) #ASH25

121

Mark Geyer, M.D. @markgeyermd.bsky.social · 08/12/2025

Nicolò Peccatori presents on PAX5r B-ALL in 162 pediatric pts treated on consecutive AIEOP-BFM ALL trials in Italy/Germany/Austria. 60 PAX5 fusion partners seen. Trend toward more IKZF1-plus, ↑WBC and NCI-HR. Analysis of prospectively identified pts (vs controls): no diff in MRD resp (1/2) #ASH25

100

Mark Geyer, M.D. @markgeyermd.bsky.social · 08/12/2025

Sankalp Anora of @mdanderson.bsky.social presents on risk factors for relapse in 213 pts receiving frontline blinatumomab in any phase of treatment. 2y cumulative incidence relapse ~11.4%. Descriptive analysis of factors associated w/ relapse below. (1/2) #ASH25

111

Mark Geyer, M.D. @markgeyermd.bsky.social · 08/12/2025

Sumit Gupta from @sickkidsto.bsky.social presents an update from AALL1731 (previously showed DFS benefit w/ blina + chemo in SR-avg and SR-high in pediatric B-ALL). In pts randomized to blina, Hispanic ancestry, EOI MRD were no longer negative prognostic factors. Re: genetic risks... (1/2) #ASH25

111

Mark Geyer, M.D. @markgeyermd.bsky.social · 08/12/2025

Ruth Wang'ondu from @stjuderesearch.bsky.social presents on pediatric pts w/ NCI-SR ALL at dx (age 1-<10, WBC <50k/mcL) receiving 3-drug induction on AALL0932 -> reclassified as NCI-HR/VHR based on pathologic/MRD findings (could be enrolled on AALL1131 -> aBFM backbone w/ randomizations. 1/2 #ASH25

200

Mark Geyer, M.D. @markgeyermd.bsky.social · 07/12/2025

Amanda DiNofia @childrensphila.bsky.social presents on tisa-cel for 1st CNS relapse in pediatric B-ALL (group that did NOT benefit from blina in AALL1331). 43 pts w/ CNS relapse (age 0-29, 1st in 39/43) w/o cXRT for relapse rec'd tisa-cel. At d28, 41/42 evaluable pts in CNS remission. (1/2) #ASH25

100

Mark Geyer, M.D. @markgeyermd.bsky.social · 07/12/2025

Dr. Ying Wang presents updated Ph1b/2 study data w/ MK-1045 (humanized bispecific IgG4 CD19xCD3 T-cell engager) in R/R B-ALL. Long-half life allows weekly IV admin (not IVCI). 75 pts treated, 10 dose levels; 73 efficacy-evaluable. CR/CRi/CRh in 55% (83% w/ dose ≥60mg). 9 w/ (1/2) #ASH25 prior blina

121

Mark Geyer, M.D. @markgeyermd.bsky.social · 07/12/2025

Dr. Lucy Cain of @childrensphila.bsky.social presents on humanized CD19-targeted CAR T-cell product (huCART19) for R/R B-ALL (HR and post-CAR relapse): 100 pts age 0-29 treated (52 CAR naive, 48 CAR exposed). Majority pts had MRD or less at tx. 94%/77% CR/Cri d28 (CAR naive/exposed). (1/2) #ASH25

100

Mark Geyer, M.D. @markgeyermd.bsky.social · 07/12/2025

Marlise Luskin from @danafarber.bsky.social presents on inotuzumab/venetoclax (ino/ven) in R/R B-ALL/LBL -> induction w/ 1-2 28d cycles of ven added to ino. If CR, consolidation w/ 21d ven + ino for up to 6 cycles. Dex given prephase + w/ induction. 23 pts enrolled (4 Ph+), no DLTs. (1/2) #ASH25

100

Mark Geyer, M.D. @markgeyermd.bsky.social · 07/12/2025

Gowrishankar Palaniswamy presents on EfficientNetB1, an AI application reviewing blood smears/marrow (BM) studies in pts w/ ALL. Goal to distinguish benign lymphocytes from ALL and assign early pre-B, pre-B, and pro-B classification. Highly reproducible without loss over epochs. (1/2) #ASH25

100

Mark Geyer, M.D. @markgeyermd.bsky.social · 07/12/2025

Nicholas Short of @mdanderson.bsky.social presents paired analysis of NGS for IgH/TCR and PCR for BCR::ABL1 in 80 adults w/ Ph+ ALL w/ clonoSEQ MRD neg. Strong correlation between FISH+ in segmented nuclei at dx and PCR+/NGS- state later. NGS-/PCR- vs NGS-/PCR+ w/ similar OS/relapse. (1/2) #ASH25

111

Mark Geyer, M.D. @markgeyermd.bsky.social · 07/12/2025

Rohaum Hamidi of @stanfordmedicine.bsky.social presents study of clonoSEQ to measure disease burden and B-cell load prior to LD chemo and CAR T-cell therapy. 60 pts age 1-26 treated w/ CD19, CD22, or dual CD19/22 CAR T-cells at Stanford. Peak sequence abundance assoc w/ better EFS/OS. (1/2) #ASH25

100

Mark Geyer, M.D. @markgeyermd.bsky.social · 07/12/2025

Dr. Roberta Azevedo of @mdanderson.bsky.social presents on predictors of relapse post-blina/inotuzumab (ino) w/ or w/o alloHCT: 203 adults in first salvage. 65 pts received blina/ino, 71 received ino alone, 36 received BLIN alone, 117 received chemo w/ ino or BLIN ->172/203 CR. (1/2) #ASH25

110

Reposted by Mark Geyer, M.D.

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 07/12/2025

#ASH25 #bmtsm Jiang: no role for FLT3i maintenance in pts MRD neg at d30 who don’t have high risk factors (ELN22 adv, relapse, MRD pos pre-HCt), but in high risk pts there was benefit for maintenance even if d30 MRD neg. FLT3i used for at least one year.

031

Mark Geyer, M.D. @markgeyermd.bsky.social · 07/12/2025

Matthew Wieduwilt presents follow-up data from Alliance (A041703) study for adults ≥60y w/ Ph-neg B-ALL. Single agent ino x1-2 cycles adapted to response ->3-4 cycles of blina. Summary of other frontline inotuzumab (ino)-based regimens below. 33 patients (median age 71, range 60-84). (1/2) #ASh25

120

Mark Geyer, M.D. @markgeyermd.bsky.social · 07/12/2025

Ibrahim Aldoss of @cityofhope.bsky.social presents study of 18 pts age 55 and up w B-ALL in CR1 following any initial therapy (w/o immediate plan for HCT) treated w/ single dose of 4-1BB CD19-targeted CAR T-cells as consolidation. No DLT in safety lead-in (n=6); 12 add'l pts enrolled. (1/2) #ASH25

110

Mark Geyer, M.D. @markgeyermd.bsky.social · 07/12/2025

Dr. Runxia Gu presents data from a phase 2 study from China utilizing CAR T-cells as 1L consolidation for Ph+ ALL. Schema: overembatinib, vincristine, pred and venetoclax as induction -> 1-2 cycles of TKI + pred/ven consolidation -> 4-1BB CD19-targeted CAR-T-> ven/TKI + POMP maintenance (1/2) #ASH25

101

Mark Geyer, M.D. @markgeyermd.bsky.social · 07/12/2025

@anand-88-patel.bsky.social from Univ of Chicago presents on a TKI + inotuzumab (ino) combinations for new dx Ph+. 1° endpoint: MR3 after 2 courses of therapy. Scheme 1: DAS , dex, ino -> TKI + POMP; change DAS to PON if no Mr4 after C2. Some VOD seen -> Scheme 2: Lower dose/less ino. #ASH25 (1/2)

121

Mark Geyer, M.D. @markgeyermd.bsky.social · 07/12/2025

Yosr Hicheri presents EWALL-PH03 study of imatinib (IMA) vs ponatinib (PON) w/ low-intensity chemo in pts ≥55y with newly diagnosed Ph+ ALL; 3rd arm of PON/blina stooped for financial reasons. 1° endpoint: MR4 after consolidation; 2°: EFS. More HTN in PON arm. No CNS relapses ((1/2) #ASH25

100

Mark Geyer, M.D. @markgeyermd.bsky.social · 07/12/2025

Dr. Chiaretti of GIMEMA presents results of RCT of ponatinib + blina (vs imatinib + chemo), 2:1 randomization, 236 enrolled, around 30% IKZF1-plus. Higher rates of molecular response (71% vs 49%) w/ pon/blina. Reduced utilization of transplant noted vs D-ALBA. (1/2) #ASH25

111

Mark Geyer, M.D. @markgeyermd.bsky.social · 06/12/2025

Petri Polonen of @stjuderesearch.bsky.social discusses "TALLForest," an automated multi-omic classifier. Group has previously distinguished T-ALL subtypes using RNAseq and here used gene expression and WGS data from large RCT (AALL0434) from pts age 1-29 w/ T-ALL/LBL. (1/2) #ASH25

110

Mark Geyer, M.D. @markgeyermd.bsky.social · 06/12/2025

Carol Fries from @urochester.bsky.social presents on IgH clonal diversity in B-ALL; diverse V-DJ subclones (20% of pts) are often non-trackable + distinct clones may respond differently to tx. scRNQseq + CYTOF in pt samples showed V-DJ rearr. state uncoupled from cell development state.(1/2) #ASH25

100

Mark Geyer, M.D. @markgeyermd.bsky.social · 06/12/2025

Jason Xu (@stjuderesearch.bsky.social) reports on impact of VNTR in TPMT promoter region (beyond coding variants in TPMT). Hypothesis: ↑ VNTR repeats associated w/ ↓ enzymatic activity of TPMT & ↑myelosuppression 2/2 thiopurines. Genotype pipeline below. Allele types vary w/ ancestry. (1/2) #ASH25

130

Mark Geyer, M.D. @markgeyermd.bsky.social · 06/12/2025

Michael Andreeff from @mdanderson.bsky.social presents on generaing iPS-derived MSCs secreting IL7/15. MSCs heteroeneous -> iMSC less heterogeneous; retain differentiation capacity, better proliferation. IL-7 may promote T-cell survival and IL-15 may enhance proliferation and cytotox. (1/2) #ASH25

100

Mark Geyer, M.D. @markgeyermd.bsky.social · 06/12/2025

Ilio Leontari from Imperial College London presents on one potential approach to address leptomeningeal disease (LMD) in ALL and MM -> iNKT cells (invariant TCR recognises lipid antigens presented by CD1d, MHC class I-like glycoprotein) have higher higher expression of ITGA4/ITGB1. (1/2) #ASH25

100

Mark Geyer, M.D. @markgeyermd.bsky.social · 06/12/2025

Dr. Rizman Romee presents on cytokine-induced memory-like (CIIML) NK cells in combination w/ BHV-1100, an antibody recruiting molecule (ARM) -> binds CD38 on MM and CD16 (via IgG) on NK cells -> enhances NK activation, CIML activity in animal model w/o NK fratricide. Ph 1 trial done (1/2) #ASH25

110

Mark Geyer, M.D. @markgeyermd.bsky.social · 06/12/2025

Dr. Andrew McIntyre from Univ of Oxford presents on biological outcomes of prophylactic transfer of CD4+ T-cells post alemtuzumab-based, RIC matched related donor HCT for heme malignancy -> increase in CD4+ TFH population + marked reduction in CD8+ effector cell accumulation. (1/2) #ASH25 #BMTsm

100

Mark Geyer, M.D. @markgeyermd.bsky.social · 06/12/2025

Ho Ngai from @mdanderson.bsky.social: identified expanded, polyclonal T-cell responses vs 29 known/novel neoantigen peptide::HLA complexes in myeloid dz-> TCR T-cells generated/tested -> TCR-T to DNMT3A:R882H on HLAA*01:01 or IDH2:R140Q on HLA-B*07:02 -> selective killing of 1° human AML. #ASH25

000

Reposted by Mark Geyer, M.D.

Sara R. Fagerlie, PhD, CHCP @cancercommunicator.com · 06/12/2025

#ASH25 (Abs 47): Encouraging early results (N=21, median age 70 y) from ph2 SAVE trial of all-oral regimen: revumenib + decitabine/cedazuridine + venetoclax in ND NPM1- or KMT2A-mutated AML. 86% ORR, 81% CR/CRh. #Medsky #cansky #oncsky #AML www.cancercommunicator.com/oral-menin-b...

031

Mark Geyer, M.D. @markgeyermd.bsky.social · 06/12/2025

Alberto Peloso (Univ of Padua) presents on myelomonocytic lineage (mm-SW) in B-ALL using single cell analysis. At dx, early differentiation block. Monocyte-like profile at day 15 w/ evidence of transcriptional reprogramming incl distinct patterns by DNA methylation profiling. (1/2) #leusm #ASH25

121

Mark Geyer, M.D. @markgeyermd.bsky.social · 06/12/2025

Dr. Mehta of @childrensphila.bsky.social presents on selection of myeloid subclones following chemo for HR B-ALL (KMT2Ar, Ph-like, Ph+, iAMP21). Comprehensive profiling on samples at dx & end-induction MRD included scRNA-seq, scATAC-seq, scDNA-seq, CITE-seq, spectral flow (1/2) #ASH25

101

Mark Geyer, M.D. @markgeyermd.bsky.social · 06/12/2025

Siyuan Liu discusses the rare, ultra-high risk subtype of TCF3::HLF B-ALL. 34 cases in series. Most w/ CD13 and/or CD33 expression. Transcriptomic overlap between isoforms noted. Isolated RAS pathway mutations in majority of cases. Blina/CAR T-cells effective in achieving MRD-neg state (1/2) #ASH25

101

Mark Geyer, M.D. @markgeyermd.bsky.social · 06/12/2025

Benjamin Simpson (Autolus) presents data from pivotal FELIX trial (R/R B-ALL) correlating drug product (DP) and leukapheresis product (LP) T-cell phenotypes w/ outcomes. Greater % Tcm in DP assoc w/ better OS; poor correlation between LP and DP phenotypes noted. #ASH25 #leusm

001

Reposted by Mark Geyer, M.D.

Steve Vladeck @stevevladeck.bsky.social · 23/10/2025

#SCOTUS denies a stay of execution to Alabama death-row prisoner Anthony Boyd, over *quite* a dissent from the three Democratic appointees, written by Justice Sotomayor, about the problems with nitrogen hypoxia as a method of execution: www.supremecourt.gov/opinions/25p...

Take out your phone, go to the clock app, and find the
stopwatch. Click start. Now watch the seconds as they
climb. Three seconds come and go in a blink. At the thirtysecond mark, your mind starts to wander. One minute
passes, and you begin to think that this is taking a long
time. Two . . . three . . . . The clock ticks on. Then, finally,
you make it to four minutes. Hit stop.
Now imagine for that entire time, you are suffocating.
You want to breathe; you have to breathe. But you are
strapped to a gurney with a mask on your face pumping
your lungs with nitrogen gas. Your mind knows that the
gas will kill you. But your body keeps telling you to breathe.
That is what awaits Anthony Boyd tonight. For two to
four minutes, Boyd will remain conscious while the State of
Alabama kills him in this way. When the gas starts flowing, he will immediately convulse. He will gasp for air. And

he will thrash violently against the restraints holding him
in place as he experiences this intense psychological torment until he finally loses consciousness. Just short of
twenty minutes later, Boyd will be declared dead.
Boyd asks for the barest form of mercy: to die by firing
squad, which would kill him in seconds, rather than by a
torturous suffocation lasting up to four minutes. The Constitution would grant him that grace. My colleagues do not.
This Court thus turns its back on Boyd and on the Eighth
Amendment’s guarantee against cruel and unusual punishment. Because the Court should have instead granted a
stay of execution and Boyd’s petition for certiorari, I respectfully dissent.

38629232

Reposted by Mark Geyer, M.D.

Matthew Cobb @matthewcobb.bsky.social · 07/09/2025

Co-discoverer of reverse transcriptase at 32, Nobel Prize at 37, played a key role at the 1975 Asilomar comference.

nytimes.com

David Baltimore, Nobel-Winning Molecular Biologist, Dies at 87

014567

Mark Geyer, M.D. @markgeyermd.bsky.social · 06/09/2025

Carlo Acutis will likely be the first saint with Pokémon mentioned in his bio; I'd like to think he'd share my enthusiasm for Quaxly. Beyond the hype of being a patron saint of gamers, however, I find it more compelling that he lived in our context and reminds us of God's presence in all things. 1/2

aftermath.site

The Politics, Theology, And Hype Behind The First Gamer Saint - Aftermath

Teenager Carlo Acutis, set to be canonized at the end of this month, will be the Catholic Church's first millennial saint

120